
Agios To Highlight Pyruvate Kinase Activation Portfolio With New Data In Rare Blood Disorders At 30Th EHA Congress
(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that …